Professor John McMurray: Improving SGLT2 Inhibitor Prescribing Rates


Professor John McMurray explains why he is not as displeased as some colleagues are with the uptake of SGLT2 inhibitor prescribing rates for patients with heart failure or chronic kidney disease.

As part of their coverage of the American Heart Association (AHA) Scientific Sessions 2020, our sister publication Practical Cardiology has been busy interviewing leading experts in the field of cardiometabolic health. Among the most common talking points from this year’s annual meeting was further implementation of antihyperglycemic agents in real-world practice.

In the past 2 years, major outcomes trials have stolen the show at annual cardiology meetings, but now that focus has shifted to improving prescribing rates. However, there are still multiple presentations underlining new data and analyses from these major trials that continue to push our understanding of these drug classes forward.

For more on the topic of prescribing rates for SGLT2 inhibitors, check out this interview with John McMurray, MD, professor of cardiology at the University of Glasgow, as he offers his perspective in a recent AHA House Call.

Recent Videos
Brendon Neuen, MBBS, PhD | Credit:
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
A panel of 5 cardiovascular experts
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
© 2024 MJH Life Sciences

All rights reserved.